fluoxetine and bay 63-2521

fluoxetine has been researched along with bay 63-2521 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allanore, Y; Avouac, J; Becker, M; Clements, P; Cutolo, M; Czirjak, L; Damjanov, N; Del Galdo, F; Denton, CP; Distler, JHW; Distler, O; Figelstone, K; Foeldvari, I; Fransen, J; Frerix, M; Furst, DE; Guiducci, S; Herrick, AL; Hunzelmann, N; Khanna, D; Kowal-Bielecka, O; Kulak, A; Matucci-Cerinic, M; Müller-Ladner, U; Riemekasten, G; Silver, R; Smith, V; Sulli, A; Tarner, I; Tyndall, A; Valentini, G; van den Hoogen, F; van Laar, JM; Walker, UA; Welling, J; Wigley, F; Zulian, F1

Reviews

1 review(s) available for fluoxetine and bay 63-2521

ArticleYear
Update of EULAR recommendations for the treatment of systemic sclerosis.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; Fingers; Fluoxetine; Gastrointestinal Diseases; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Kidney Diseases; Lung Diseases; Phosphodiesterase 5 Inhibitors; Prostaglandins I; Pyrazoles; Pyrimidines; Raynaud Disease; Rheumatology; Scleroderma, Systemic; Selective Serotonin Reuptake Inhibitors; Ulcer

2017